In recent years, a class of medications based on GLP-1 (glucagon-like peptide-1) has transformed our understanding of metabolic health. To truly grasp this development’s significance, we must first understand what GLP-1 is and how it works in our bodies.

What is GLP-1 and How Does it Work?

GLP-1 is a naturally occurring hormone that serves as a master regulator of several crucial metabolic processes. When we eat, specialized cells in our intestines release GLP-1, which then triggers a series of effects throughout our body. Think of GLP-1 as a conductor in an orchestra, coordinating multiple musicians (our organs and systems) to play in perfect harmony. The hormone works through three main pathways:

Brain: GLP-1 communicates with our appetite control centers in the brain, helping us feel satisfied with our meals. This is similar to how a thermostat regulates temperature. When enough food has been consumed, GLP-1 signals that we’ve reached our “set point” and can stop eating.

Pancreas: GLP-1 helps the pancreas manage blood sugar by stimulating insulin production when needed and reducing glucagon (a hormone that raises blood sugar). This dual action creates a balanced approach to blood sugar control, like having a gas pedal and brake in a car.

Digestive System: In the digestive system, GLP-1 slows down the rate at which food leaves our stomach. This gradual release of nutrients helps prevent sudden spikes in blood sugar and prolongs the feeling of fullness.

What Physiological Processes Does GLP-1 Impact?

Metabolic

GLP-1 creates widespread improvements in metabolism. These changes extend beyond blood sugar control, affecting everything from liver function to fat storage patterns.1

Stimulates Insulin Secretion

GLP-1 is primarily known for enhancing insulin secretion in response to nutrient intake, mainly carbohydrates. It acts on pancreatic β-cells to increase insulin release, thereby lowering blood glucose levels in a glucose-dependent manner.2

Suppresses Glucagon Secretion

GLP-1 also inhibits glucagon release from pancreatic α-cells. Glucagon normally raises blood glucose levels by stimulating the liver to produce glucose. By suppressing glucagon, GLP-1 helps reduce hepatic glucose output.3

Slows Gastric Emptying

GLP-1 slows gastric emptying, which prolongs the digestion process and helps to reduce postprandial blood glucose spikes. This action promotes satiety and aids in the regulation of appetite.4

Promotes Satiety and Reduces Appetite

GLP-1 acts on the central nervous system (CNS), particularly in the hypothalamus, to induce a feeling of fullness (satiety).5

Improves β-Cell Function and Proliferation

GLP-1 has a trophic effect on pancreatic β-cells. It promotes β-cell proliferation, inhibits β-cell apoptosis and enhances insulin gene expression, which can improve pancreatic function over time.6

Broader Health Impact

While GLP-1-based medications have gained fame for their weight loss effects, their influence on health extends much further. Research has revealed several significant benefits:

Cardioprotective Effects

GLP-1 has been shown to benefit the cardiovascular system, including improving endothelial function, reducing blood pressure and exerting anti-inflammatory effects.7 A major study published in the New England Journal of Medicine found that patients using GLP-1 medications had fewer heart attacks and strokes. This protective effect appears to work independently of weight loss, suggesting that GLP-1 directly benefits heart health.8

Neuroprotective Effects

Emerging evidence indicates that GLP-1 has neuroprotective effects, such as reducing oxidative stress, promoting neuronal survival, and possibly enhancing cognitive function.9 Scientists have also found that GLP-1 may help safeguard our brain cells. Recent research published in Nature Medicine suggests these medications could lower the risk of developing dementia.10 This discovery has opened exciting possibilities for treating neurodegenerative diseases.

The Technology Revolution in GLP-1 Treatment

Modern technology has transformed how we use and monitor GLP-1 treatments. This integration of medicine and technology is creating more personalized and effective treatment approaches:

Artificial Intelligence in Patient Care

Imagine having a highly skilled medical assistant available 24/7 to monitor your treatment progress. This is becoming possible through AI systems that can:

• Analyze patterns in patient responses to medications

• Predict when side effects might occur

• Suggest optimal times for medication doses

• Help identify which patients might benefit most from treatment.

Digital Health Integration

Modern GLP-1 treatments often work within a broader digital health ecosystem. Smart devices can track vital signs and symptoms, while apps provide real-time guidance and support. This continuous monitoring and adjustment helps ensure treatments are as effective as possible.

Public Health Implications: A Double-Edged Sword

The widespread adoption of GLP-1 medications has created both opportunities and challenges for public health:

The Positive Impact

These treatments have shown remarkable effectiveness in addressing several major health concerns:

• Reduced rates of obesity-related complications

• Better management of type 2 diabetes

• Improved heart health outcomes

• Potential cognitive benefits

• Potential benefits for alcohol and drug dependence.11

The Challenges

Several significant concerns need to be addressed:

• Cost and access issues create treatment disparities

• Limited long-term data on extended use

• Supply chain pressures affecting medication availability

• Questions about effects on gut health and the microbiome.

The Natural Alternative: Supporting Our Body’s GLP-1

In medicine, “supporting the body” refers to a treatment approach that aims to assist the body’s natural healing mechanisms by providing necessary support and interventions that work with the body’s physiology.

Example: A doctor recommends dietary changes and exercise for someone with high blood pressure rather than immediately prescribing medication.

Supporting the body’s natural production of GLP-1 is quite different than giving the body a “drug” version. GLP-1 agonists are not GLP-1 but a modified version of GLP-1 that is more active on a receptor. Natural GLP-1 is broken down quickly (the body’s natural process) versus GLP-1 agonists, which are designed to resist being broken down (allowing them to stay in the bloodstream longer).12

Supporting the body’s natural production of GLP-1 can provide benefits. In an ideal situation, the goal would be to seek natural alternatives to help support the body’s natural production of GLP-1 and avoid the potential for undesirable side effects caused by its pharmaceutical counterpart (GLP-1 agonist).

The Future is Bright

The field of GLP-1 research and treatment continues to evolve rapidly. We’re seeing development in several exciting areas:

• More sophisticated AI systems for treatment optimization

• New medication delivery methods

• Comprehensive digital health platforms

• Better ways to predict treatment responses

• New science validating dietary ingredients as safe and effective support of GLP-1.

The GLP-1 story represents a fascinating intersection of biology, medicine and technology. While these treatments have shown remarkable promise in addressing various health challenges, their optimal use likely involves a balanced approach combining medical innovation with support for natural bodily processes. As our understanding grows and technology advances, we may find even more effective ways to harness the power of GLP-1 for better health outcomes. NIE

References:

1 Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Araújo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA. GLP-1a: Going beyond Traditional Use. Int J Mol Sci. 2022 Jan 10;23(2):739. doi: 10.3390/ijms23020739. PMID: 35054924; PMCID: PMC8775408.

2 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. doi: 10.1152/physrev.00034.2006. PMID: 17928588.

3 Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993 Jan;91(1):301-7. doi: 10.1172/JCI116186. PMID: 8423228; PMCID: PMC330027.

4 Maselli DB, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Adv Exp Med Biol. 2021;1307:171-192. doi: 10.1007/5584_2020_496. PMID: 32077010.

5 Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20. doi: 10.1172/JCI990. PMID: 9449682; PMCID: PMC508592.

6 Maselli DB, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Adv Exp Med Biol. 2021;1307:171-192. doi: 10.1007/5584_2020_496. PMID: 32077010.

7 Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012 Apr;33(2):187-215. doi: 10.1210/er.2011-1052. Epub 2012 Feb 8. PMID: 22323472; PMCID: PMC3528785.

8 Marso S, Daniels G, Bown-Frandsen K, et.al., Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med 2016;375:311-322, DOI: 10.1056/NEJMoa1603827.

9 Erbil D, Eren CY, Demirel C, Küçüker MU, Solaroğlu I, Eser HY. GLP-1’s role in neuroprotection: a systematic review. Brain Inj. 2019;33(6):734-819. doi: 10.1080/02699052.2019.1587000. Epub 2019 Apr 2. PMID: 30938196.

10 Bowe, B., Xie, Y. & Al-Aly, Z. Postacute sequelae of COVID-19 at 2 years. Nat Med 29, 2347–2357 (2023). https://doi.org/10.1038/s41591-023-02521-2.

11 Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022 Feb;179(4):625-641. doi: 10.1111/bph.15677. PMID: 34532853; PMCID: PMC8820218.

12 Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab. 2017 Mar;22(1):15-26. doi: 10.6065/apem.2017.22.1.15. Epub 2017 Mar 31. PMID: 28443255; PMCID: PMC5401818.

David Foreman is a pharmacist, author, speaker and media personality known internationally as “The Herbal Pharmacist.” His background in pharmacy and natural medicine puts Foreman in an elite class of health experts. A graduate of the University of South Carolina College of Pharmacy, Foreman currently consults with leading ingredient suppliers, helping them turn their clinical studies into digestible content through papers, webinars, seminars, and books. He is also a regular contributor to most of the industry’s leading publications and trade events.